{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-336716","form_type":"8-K","ticker":"RGNX","cik":"0001590877","company_name":"REGENXBIO Inc.","filed_at":"2026-08-06T11:10:16+00:00","discovered_at":"2026-08-06T11:15:03.438163+00:00","generated_at":"2026-08-06T11:15:37.710666+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"REGENXBIO Q2 net income $22.7M; RGX-202 BLA on track; cash runway to Q4 2027","bullets":["Net income of $22.7M ($0.43 per share) vs net loss of $70.9M in Q2 2025; revenue $108.0M (incl. $100M AbbVie milestone).","RGX-202 Phase III AFFINITY DUCHENNE trial met primary endpoint (p<0.0001); BLA submission on track for Q3 2026 with potential accelerated approval 2H 2027.","RGX-121 BLA resubmission on track for Q3 2026 after positive FDA Type A meeting; no additional studies required.","Sura-vec (ABBV-RGX-314) pivotal wet AMD data expected Q4 2026; first patient dosed in NAAVIGATE DR study triggered $100M milestone.","Pro forma cash ~$313M after July 2026 milestone and public offering; cash runway extended into Q4 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-336716","json":"https://secwatch.observer/filing/0001193125-26-336716.json","markdown":"https://secwatch.observer/filing/0001193125-26-336716.md","text":"https://secwatch.observer/filing/0001193125-26-336716.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1590877/000119312526336716/0001193125-26-336716-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1590877/000119312526336716/rgnx-20260806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T11:15:37.710666+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}